Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
SAN CLEMENTE, CA — Virginia Ruth Sanzone, Vice President and General Counsel at ICU Medical Inc. (NASDAQ:ICUI), a $3.3 billion medical technology company, has sold 700 shares of the company’s common stock. According to InvestingPro data, while ICU Medical wasn’t profitable over the last twelve months, analysts expect positive earnings this year. The shares were sold at a price of $133.6244 each, totaling $93,537. This transaction leaves Sanzone with a remaining direct ownership of 6,386 shares.
The sale was executed on May 30, 2025, according to a recent SEC filing. All shares were sold at the exact disclosed price, as noted in the filing’s footnotes.
In other recent news, ICU Medical reported strong financial results for the first quarter of 2025, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $1.72, significantly above the forecasted $1.27. The company also reported revenue of $599 million, exceeding the anticipated $567.08 million, reflecting a 10% growth in constant currency terms. Despite the positive earnings, Needham maintained a Hold rating on ICU Medical’s stock, citing the company’s valuation as considerably higher than its peers with similar growth rates. Additionally, ICU Medical finalized a joint venture with Otsuka, focusing on IV Solutions, which became effective on May 1, 2025. The company anticipates a tariff impact of $25-30 million, primarily in the second half of the year, but expects favorable currency exchange rates and internal mitigation efforts to reduce this impact to $5-10 million. ICU Medical’s management has maintained its full-year 2025 guidance but projects to hit the lower end of the ranges due to these tariff pressures. Furthermore, ICU Medical expanded its stock incentive plan, increasing the total number of shares available for issuance by 2,150,000, aligning the interests of employees and directors with those of shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.